Publication:
The potential use of metabolic cofactors in treatment of NAFLD

dc.contributor.coauthorMardinoğlu, Adil
dc.contributor.coauthorYüksel, Hatice Hilal
dc.contributor.coauthorUhlen, Mathias
dc.contributor.coauthorBoren, Jan
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorUral, Dilek
dc.contributor.kuauthorZeybel, Müjdat
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:12:03Z
dc.date.issued2019
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue7
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipKnut and Alice Wallenberg Foundation
dc.description.versionPublisher version
dc.description.volume11
dc.identifier.doi10.3390/nu11071578
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR01686
dc.identifier.issn2072-6643
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85070473044
dc.identifier.urihttps://hdl.handle.net/20.500.14288/1129
dc.identifier.wos478885400021
dc.keywordsNutrition and dietetics
dc.keywordsNAFLD
dc.keywordsMetabolic cofactors
dc.keywordsl-carnitine
dc.keywordsNicotinamide riboside
dc.keywordsl-serine
dc.keywordsN-acetyl-l-cysteine
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.grantno20170303
dc.relation.ispartofNutrients
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8331
dc.subjectMedicine
dc.subjectGastroenterology and hepatology
dc.titleThe potential use of metabolic cofactors in treatment of NAFLD
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorUral, Dilek
local.contributor.kuauthorZeybel, Müjdat
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
8331.pdf
Size:
302.2 KB
Format:
Adobe Portable Document Format